Docosahexaenoic Acid Slows Visual Field Progression in X-Linked Retinitis Pigmentosa: Ancillary Outcomes of the DHAX Trial | Zendy

Dennis R. Hoffman | Zendy; Dianna K. Hughbanks-Wheaton | Zendy; Rand Spencer | Zendy; Gary E. Fish | Zendy; N. Shirlene Pearson | Zendy; YiZhong Wang | Zendy; Martin Klein | Zendy; Alison Takacs | Zendy; Kirsten G. Locke | Zendy; David G. Birch | Zendy

Open Access

Docosahexaenoic Acid Slows Visual Field Progression in X-Linked Retinitis Pigmentosa: Ancillary Outcomes of the DHAX Trial

Author(s) -

Dennis R. Hoffman,

Dianna K. Hughbanks-Wheaton,

Rand Spencer,

Gary E. Fish,

N. Shirlene Pearson,

YiZhong Wang,

Martin Klein,

Alison Takacs,

Kirsten G. Locke,

David G. Birch

Publication year - 2015

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.15-17786

Subject(s) - retinitis pigmentosa , docosahexaenoic acid , medicine , visual acuity , placebo , ophthalmology , visual field , randomized controlled trial , electroretinography , retinal , polyunsaturated fatty acid , biology , fatty acid , pathology , biochemistry , alternative medicine

Docosahexaenoic acid (DHA) was supplemented in a single-site, placebo-controlled, randomized clinical trial designed to slow vision loss associated with X-linked retinitis pigmentosa (XLRP); the DHAX Trial. We previously reported no significant differences between supplemented and placebo groups in intent-to-treat analysis of primary ERG outcomes. Assessed herein are hypothesis-generating measures of ancillary visual function outcomes in participants fully adhering to trial protocol.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research